29-30 SEPTEMBER 2015 | THE MAJESTIC HOTEL, BARCELONA POST EVENT REPORT CELL & GENE THERAPY EUROPE 127 Organisations 20 Countries 220+ Attendees 75 Speakers 73% Director and above Silver sponsors Bronze sponsors THANKS TO OUR SPONSORS WWW. CGTEUROPE.COM Gold Sponsor "We've met a lot of new companies and made a lot of new contacts. We are dealing with a global industry now. We have found it hugely beneficial and will definitely be coming again." Robert Jones, General Manager, Fisher Bioservices
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
29-30 SEPTEMBER 2015 | THE MAJESTIC HOTEL, BARCELONA
POST EVENT REPORT
CELL & GENE THERAPY EUROPE
127Organisations
20Countries
220+Attendees
75Speakers
73%Director
and above
Silver sponsors Bronze sponsors
THANKS TO OUR SPONSORS
WWW.CGTEUROPE.COM
Gold Sponsor
"We've met a lot of new companies and made alot of new contacts. We are dealing with a globalindustry now. We have found it hugely beneficialand will definitely be coming again."Robert Jones, General Manager, Fisher Bioservices
WWW.CGTEUROPE.COM
EXPERT SPEAKERS AT THE EVENT INCLUDED
MISSED CELL &GENE THERAPY
EUROPE?
SEE ALL THE ACTION FROMTHE EVENT ONLINE HERE
“It was a very interesting event as allparticipants, including speakers wereready to exchange, even on the mostchallenging subjects such asreimbursement, GMP guidance.”Bertrand Alexandre, Director, MarketingEurope, Celyad
“Real forward-thinking combiningexperts in the field from manufacturing,regulatory and value vision” – “greatnetwork with strong experience andsharing risks & opportunities” Jean-Philippe Combol, Chief OperatingOfficer, GenSight Biologics
"I want to reinforce the comments youhave received that the Conference inBarcelona was excellent in content,interactions and atmosphere.”Dr Carlos Plata, Chief Scientific Officer, ChiefMedical Officer & Head of R&D, Esteve
Dr Ruxandra Draghia-Akli, Director, HealthDictorate, Research &Innovation DG,European Commission
Michael Covington,Principal CMCRegulatory Affairs Policy& Strategy, Juno
Dr Christian Meyer,Chief Medical Officer,uniQure
Dr Marcos Timon,Head of Service,AEMPS; Member,Committee forAdvanced Therapies(CAT)
Dr Kush Parmar,Partner, 5AM Ventures
Edward Lanphier, President & ChiefExecutive Officer,Sangamo BioSciencesInc; Chairman,Alliance ofRegenerativeMedicine (ARM)
Dr Leeza Osipenko,Associate Director, NICEScientific Advice,National Institute forHealth & CareExcellence (NICE)
Dr Francois Meyer, Advisor to the President,International Affairs,Haute Autorité deSanté (HAS)
Dr Fatiha Sadallah, Principal ScientificManager, Innovative MedicinesInitiative
Prof. Chris Mason,Chair of RegenerativeMedicine Bioprocessing,University CollegeLondon
Ajan Reginald, Chief Executive Officer, Cell therapy Limited
Dr Maria Cristina Galli, Co-chair of the ATMPplatform, EATRIS-ERIC, the EuropeanInfrastructure forTranslationalMedicine; Departmentof Cell Biology andNeurosciences,Istituto Superiore diSanità
Dr Joern-Peter Halle, Senior Vice President,Global Head of ExternalInnovation, Merck Serono
Dr Maria Pascual,VP Regulatory Affairs &Corporate Quality,TiGenix
Dr Sven Kili,Vice President & Head ofGene TherapyDevelopment,GlaxoSmithKline
Lennart Åkerblom, Senior Expert, MedicalProducts Agency(MPA) Sweden &Member, Committeefor AdvancedTherapies (CAT)
Dr Anton Simeonov,Acting Deputy ScientificDirector, NationalCentre for AdvancingTranslational Sciences(NCATS), NIH
Andrea Chiesi,Director, R&D PortfolioManagement, ChiesiFarmaceutici SpA; Co-Founder & ChiefExecutive Officer,Holostem
Dr Ralf Sanzenbacher,Deputy Head of Section,Tissue-Engineering &Cell Therapeutics, Paul-Ehrlich-Institut,Federal Institute forVaccines andBiomedicinesGermany
"The conference consistently proves to be a great forum fornetworking with industry leaders in the development ofcellular and gene therapies as well as vendors for importanttechnologies and services.”Michael Covington, Principal CMC Regulatory Affairs Policy &Strategy, Juno Therapeutics, Inc
“Indeed, I found the meeting outstanding and have nonegative points (quite unusual for a regulator). Thank you foryour outstanding organizational support.”Dr Ralf Sanzenbacher, Deputy Head of Section, Tissue-Engineering & CellTherapeutics, Paul-Ehrlich-Institut, Federal Institute for Vaccines andBiomedicines Germany
21 - 22 SEPTEMBER 2016 | THE MARITIM HOTEL, BERLIN
IMMUNOTHERAPY EUROPE
CELL & GENETHERAPY EUROPE
Following the sell-out success ofCell & Gene Therapy Europe 2015,Phacilitate will be launchingImmunotherapy Europe alongsidethe 2016 edition of Cell & GeneTherapy Europe.
Join us and hundreds of cell, geneand immunotherapy executives inBerlin. Contact [email protected] or on +44 (0)207 384 7951 to findout how.
SPONSORS ALREADY CONFIRMED
JOIN US IN WASHINGTON 25 - 27 JANUARY 2016!Don’t miss the next edition of Cell & Gene Therapy World when it returns toWashington DC this January. With even more content streams, exciting new
features and an even larger audience to network and collaborate with, you can’tafford to miss the world’s premier cell and gene therapy event.